Hoba Therapeutics raises EUR 23 million in a Series A to advance new drug candidate against chronic neuropathic pain

Posted on by

COPENHAGEN, Denmark, Dec. 11, 2023 /PRNewswire/ — Hoba Therapeutics, a Novo Holdings-founded Danish biotech company dedicated to developing novel therapeutic proteins for patients living with chronic neuropathic pain and hearing loss, today announced that it has raised EUR 23 million…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.